December 8, 2025Blood

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

View Full Paper

Ask AI

Bookmark

Authors

MFMathilde FekomEuropean Society for Blood and Marrow Transplantation SGSebastian GiebelNational Institute of Oncology MAMahmoud AljurfKing Faisal Specialist Hospital & Research Centre

Discussion

Member takes

Implication

Analysis demonstrates improved progression free survival and overall survival in patients with Hodgkin lymphoma undergoing hematopoietic stem cell transplantation, indicating potential treatment optim

Key Points

Improvement in 2-year progression free survival noted at 73% in recent years for HCT.
For autologous HCT, older age and refractory status negatively influence outcomes.
Multivariate analysis illustrated critical factors like Karnofsky score affecting survival rates.
Findings highlight the effectiveness of Brentuximab vedotin in treatment before stem cell transplantation.

Cite This Study

Fekom et al. (2025) studied this question.

synapsesocial.com/papers/69362f3d4fa91c937236d4d8 https://doi.org/10.1182/blood-2025-4521

View Full Paper

Ask AI

Bookmark

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Discussion

Member takes

Implication

Key Points

Cite This Study

Hematopoietic stem cell transplantation for relapsed classical Hodgkin lymphoma: A benchmark Study on 19,498 patients from the EBMT lymphoma working party

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider